Preliminary observations on the administration of a glucagon-like peptide-1 receptor agonist on body weight and select carbohydrate endpoints in persons with spinal cord injury: A controlled case series.
The journal of spinal cord medicine(2023)
摘要
Administration of semaglutide for 26 weeks resulted in favorable changes in body composition and glycemic control, suggesting a reduced risk for the development of cardiometabolic disease in obese individuals with SCI. ClinicalTrials.gov identifier: NCT03292315.
更多查看译文
关键词
spinal cord injury,select carbohydrate endpoints,agonist,glucagon-like
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要